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Abstract
Background: The introduction of complete mesocolic excision (CME) with central vascular ligation (CVL) for right-
sided colon cancer has improved the oncologic outcomes. Recently, we have introduced a modified CME (mCME)
procedure that keeps the same principles as the originally described CME but with a more tailored approach. Some
retrospective studies have reported the favourable oncologic outcomes of laparoscopic mCME for right-sided colon
cancer; however, no prospective multicentre study has yet been conducted.
Methods: This study is a multi-institutional, prospective, single-arm study evaluating the oncologic outcomes of
laparoscopic mCME for adenocarcinoma arising from the right side of the colon. A total of 250 patients will be
recruited from five tertiary referral centres in South Korea. The primary outcome of this study is 3-year disease-free
survival. Secondary outcome measures include 3-year overall survival, incidence of surgical complications,
completeness of mCME, and distribution of metastatic lymph nodes. The quality of laparoscopic mCME will be
assessed on the basis of photographs of the surgical specimen and the operation field after the completion of
lymph node dissection.
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Discussion: This is a prospective multicentre study to evaluate the oncologic outcomes of laparoscopic mCME for
right-sided colon cancer. To the best of our knowledge, this will be the first study to prospectively and objectively
assess the quality of laparoscopic mCME. The results will provide more evidence about oncologic outcomes with
respect to the quality of laparoscopic mCME in right-sided colon cancer.
Trial registration: ClinicalTrials.gov ID: NCT03992599 (June 20, 2019). The posted information will be updated as
needed to reflect protocol amendments and study progress.
Keywords: Modified complete mesocolic excision, Laparoscopic surgery, Right-sided colon cancer, Oncologic
outcomes
Background
With the introduction of complete mesocolic excision
(CME) with central vascular ligation (CVL), the outcome
of colon cancer surgery has significantly improved [1–4].
CME in colon cancer surgery is a concept analogous to
total mesorectal excision in rectal cancer, which is based
on sharp dissection along the embryological anatomical
planes with sharp separation of the visceral fascia from
the parietal plane, leading to a surgical specimen with an
intact coverage [2, 5]. The CME technique involves on-
cologic resection with careful dissection of the mesoco-
lon along the embryological planes, resulting in the
complete mobilisation of the mesocolon covered by an
intact visceral fascia layer containing all blood vessels,
lymphatic vessels, and lymph nodes that may contain
disseminated cancer cells [1, 4]. Moreover, the method
of ligating the supplying vessels at their origin (CVL)
and removing the entire mesocolon has a considerable
effect on locoregional recurrence and improves onco-
logic outcomes [1, 3]. It is well known that excision of
specimens with an intact mesocolon is associated with
better survival rates than excision of specimens with a
defective mesocolon [3, 4].
Although Hohenberger et al. first used the term CME
with CVL [2], the concept is not necessarily new because
many institutions have already accepted similar con-
cepts. In particular, many Japanese surgeons would
argue that they have been performing a similar proced-
ure, known as D3 dissection [6]. Despite sharing similar
concepts, the technical details may differ between CME
with CVL and Japanese D3 dissection, as demonstrated
by differences in the length of resected bowels and the
area of the excised mesocolon, which seem to result
from different definitions of an adequate resection mar-
gin [7].
In practice, CME for right-sided colon cancer seems to
be more challenging because of the complexity and vari-
ability of the central vascular anatomy than with a left-
sided disease. Moreover, the original description of CME
for right-sided colon cancer indicates a very aggressive
procedure including complete Kocherization and exten-
sive extra-mesocolic lymph node dissection regardless of
the tumour location and stage, which translates to a
higher risk of serious postoperative complications, espe-
cially when performed laparoscopically [2, 8, 9].
Recently, we have introduced a modified CME
(mCME) technique for right-sided colon cancer that
keeps the same principles as the original CME procedure
but with a more tailored approach according to the loca-
tion and stage of the tumour. This tailored approach fo-
cuses on three main points: 1) achievement of an
adequate radial margin, 2) tailored lymphadenectomy ac-
cording to tumour location, and 3) selective extra-
mesocolic lymph node dissection [10].
Thus far, a considerable number of studies have shown
favourable oncologic outcomes and short-term out-
comes with the CME, mCME, and Japanese D3 types of
dissection compared with conventional surgery in right-
sided colon cancer [3, 6, 10, 11]. However, to the best of
our knowledge, no study has proven the oncologic safety
of the laparoscopic approach with objective surgical
quality assessment.
This is a multi-institutional, prospective, single-arm
study designed to evaluate the oncologic outcomes after
laparoscopic mCME for adenocarcinoma arising from
the right side of the colon, which is defined as from the
caecum up to the proximal half of the transverse colon.
In this study, the participating surgeons are assumed to
have overcome their learning curve and will be evaluated
beforehand by independent experts. The surgical quality
will be assessed on the basis of both, the resected surgi-
cal specimen and the operation field after specimen re-
moval, using submitted photographs.
Methods
Study design
This is a multi-institutional, prospective, single-arm
study. The duration of the study will be approximately 5
years (2 years of inclusion, 3 years of follow-up). Patients
will be enrolled at five tertiary colorectal cancer centres
in South Korea, including Yonsei Cancer Center, Seoul
National University Hospital, St. Vincent’s Hospital,
Kyungpook National University Chilgok Hospital, and
Korea University Anam Hospital. A complete
Yang et al. BMC Cancer          (2020) 20:657 Page 2 of 10
information leaflet will be provided to the patients dur-
ing the first consultation, and informed consent will be
obtained from them after screening. The preoperative,
intraoperative, and postoperative periods will be in
complete accordance with the usual care practices of the
centres. The baseline demographics and conditions, as
well as the perioperative details and the postoperative
occurrences, will be recorded on a previously designed
case report form. Data from each participating hospital
will be collected at the PIONEER database. Data collec-
tion forms can be assessed after login on the website.
Each hospital has access to their own dataset. The
follow-up encompasses 13 postoperative consultations:
1 month, 3 months, and every 3 months thereafter until
36 months.
Ethics approval
Before the enrolment of the first patient, approval for
this study will be obtained from the institutional review
board of each participating research centre (five tertiary
hospitals) in South Korea. Written informed consent will
be obtained from all patients for the acquisition and use
of anonymised clinical data before they are recruited,
and all investigators will conduct this study in accord-
ance with the tenets of the Declaration of Helsinki. This
study will be monitored by an independent data and
safety monitoring committee.
Study population
Patients with adenocarcinoma arising from the right side
of the colon who are indicated to undergo a laparoscopic
mCME will be eligible for this study. The right side of
the colon is defined as from caecum up to the proximal
half of the transverse colon. Investigators from each in-
stitution will be responsible for the enrolment according
to the inclusion/exclusion criteria and patient condi-
tions. The flow of participant inclusion is schematically
shown in Fig. 1.
Fig. 1 Flow chart of the study
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Inclusion criteria
 Qualitative diagnosis: a pathological diagnosis of
adenocarcinoma, with the tumour located between
the caecum and the proximal half of the transverse
colon
 Suitability for curative surgery and age > 19 years
 American Society of Anesthesiologists physical
status grade I-III
 No preoperative treatment
 Provision of written informed consent
Exclusion criteria
 Need for an emergency operation because of
conditions such as perforation or malignant colonic
obstruction
 Preoperative imaging examination results showing
distant metastasis
 Hereditary colon cancer
 History of any other malignant tumour in the recent
5 years, except for cervical carcinoma in situ that
has been cured, basal cell carcinoma, or squamous
cell carcinoma of the skin
 Simultaneous or simultaneous multiple primary
colorectal cancer
 Pregnancy or breastfeeding in women
 Patients who are not suitable to undergo
laparoscopic surgery (due to, e.g., extensive
adhesion caused by prior abdominal surgery,
inability to endure artificial pneumoperitoneum,
etc.)
 Refusal to provide informed consent
Sample size considerations
On the basis of previous data, the median 3-year
disease-free survival (DFS) rate after CME for right-
sided colon cancer is estimated to be approximately
80%, and the null hypothesis is a 3-years DFS rate
after laparoscopic mCME for right-sided colon cancer
of at least 88% [12, 13]. This will be assessed using
an exact p-value of 0.025 and a power of 0.90 based
on the Clopper-Pearson method. Thus, the sample
size is 225. The total sample size is set to 250, con-




The primary endpoint is 3-year DFS, calculated as the
time from surgery until the first objective documenta-
tion of recurrence or death from any cause.
Secondary endpoints
 The 3-year overall survival, calculated as the time
from surgery until a documented death from any
cause
 Incidence of postoperative morbidity until 4 weeks
after surgery
 Completeness of mCME, assessed by reviewing the
resected surgical specimen primarily by the
pathologist at each centre and secondarily by central
reviewers based on specimen photographs
 Central radicality, assessed by reviewing the
operative field after specimen removal primarily by
the attending surgeon at each centre and secondarily
by central reviewers based on photographs obtained
during the procedure
 Distribution of metastatic lymph nodes, assessed by
categorising the lymph nodes retrieved from
resected surgical specimens
Participating surgeons
The participating surgeons should meet the following
qualifications:
1. Has completed at least 50 cases of laparoscopic
mCME in the last 3 years.
2. Has passed the blind review of surgery video.
Briefly, the applicants will provide videos of
laparoscopic mCME performed in the last 3 months
(three cases each) to the Research Council. The
Research Council will select two videos of
laparoscopic mCME separately and randomly
appoint three experts to perform a blind peer
review. When more than two experts unanimously
approve, the applicant will be permitted to
participate in this study as a researcher.
Surgical technique
Laparoscopic mCME will be carried out with endo-
tracheal intubation under general anaesthesia. The sur-
geon should explore the abdominal cavity to determine
if there is any distant metastasis, including hepatic, peri-
toneal, mesenteric, or pelvic metastasis. Thereafter, lap-
aroscopic mCME will be performed in either a lateral-
to-medial or medial-to-lateral fashion, according to the
surgeon’s preference.
Similar to the original CME procedure, mCME re-
quires the separation of the visceral fascia from the par-
ietal fascia by sharp dissection and by ligating the
supplying vessels at their origin.
Unlike the original CME, which performs consistent
surgery regardless of the location of the right colon can-
cer, mCME has a tailored approach depending on the
tumour location (Table 1).
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First, although complete Kocherization is mandatory
in the original CME description, it may be required to
clear a possible tumour spread if the tumour is infiltrat-
ing or adhering to the duodenum or perinephric fat tis-
sue. Second, if the tumour is locally advanced, the entire
prerenal soft tissue behind Gerota’s fascia may need to
be cleared, especially for tumours growing toward the
posterior. The third difference of mCME from the con-
ventional CME involves the tailored resection of the
mesocolon and ileal mesentery according to the tumour
location. After identifying the root of the middle colic
artery, the site of the vascular ligation depends on the lo-
cation of the tumour (Fig. 2). When the tumour is lo-
cated in the caecum and ascending colon, only the right
branch of the middle colic artery is ligated. If the tumour
is present in these latter sites, the root of the middle
colic artery is ligated. If the tumour is located in the
proximal ascending colon or caecum, enough distal
ileum branches of the superior mesenteric artery (SMA)
are needed in the specimen to obtain a longer distal
ileum. As a result, the length of the distal ileum is deter-
mined by the extent of mesenteric dissection in the
mCME procedure.
Photographic documentation
The submission of three photographs is required. We
will perform a central review of the surgical procedure
by evaluating the photographs obtained during the pro-
cedure for all patients. The study-specific committee will
evaluate these photographs for quality control and surgi-
cal assessment, and the surgical procedure will be dis-
cussed at group meetings planned to be held twice a
year. Either film or digital cameras will be used to obtain
the photographs.
Table 1 CME vs. Japanese D3 vs. mCME
The original CME [2–4] Japanese D3 [6, 14] mCME [10]
Dissection plane Embryologic tissue plane between
retroperitoneal fascia and mesocolic
fascia
Along with the layers of fusion fascia Embryologic tissue plane respected, but




Not mentioned Tailored according to tumor location
and stage




Recommended Not recommended Not recommended
Securing radial margin Not clearly mentioned Not clearly mentioned Very important
Surgical quality
assessment
Specimen grading, morphometry Not clearly mentioned Specimen grading as well as surgical field
photo documentation after specimen
removal
Proximal & distal resection
margin
Not mentioned, but wide enough
bowel resection length
10-cm rule Bowel resection length determined by
tailored lymphadenectomy
a Gastroepiploic, gastrocolic trunk nodes, lymphatic tissue in pancreas capsule and other lymph nodes that are not contained in mesocolon
Fig. 2 Overview of the modified complete mesocolic excision procedure with the site of the vascular ligation depending on the location of the
tumour (red arrow) and the level of central radicality (blue arrow). a Ascending colon cancer: only the right branch of the middle colic artery is
ligated. Lymphadenectomy around the origin of the colic artery with complete exposure of the superior mesenteric vein (SMV). b Proximal
transverse colon cancer: the root of the middle colic artery is ligated. Lymphadenectomy around the origin of the colic artery with complete
exposure of the SMV and the superior mesenteric artery (SMA)
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1. Reviewing the operative field after lymph node
dissection and specimen removal based on
photographs (Fig. 3)
 A photograph displaying the central radicality
(extent of lymphadenectomy) will be obtained
between the time after ‘lymphadenectomy and
ligation of feeding arteries’ and before
‘anastomosis’.
2. Reviewing resected surgical specimens based on
photographs (Fig. 4)
 High-resolution digital colour photographs of
fresh specimens will be taken immediately after
resection.
 Photographs of the front and back sides of the
unfixed, unopened specimens, placed alongside a
metric scale, will be taken.
 The mesentery must be laid out flat without
stretching, and the site of the tumour and high
vascular ties (HVTs) should be identifiable.
Level of central radicality
The level of central radicality will be determined by
participating surgeons based on the preoperative and
intraoperative findings regarding the depth of tumour
invasion and the status of lymph node metastasis.
Central radicality will be categorised into four levels
according the extent of lymphadenectomy for central
lymph nodes and recorded as described below (Fig. 2):
I. Lymphadenectomy around the origin of the colic
artery with complete exposure of the superior
mesenteric vein (SMV) and SMA
II. Lymphadenectomy around the origin of the colic
artery with complete exposure of the SMV
III. Lymphadenectomy around the origin of the colic
artery with partial exposure of the SMV
IV. Lymphadenectomy around the origin of the colic
artery without exposure of the SMV
Tissue morphometry
By using the photographs of the resected surgical speci-
mens, tissue morphometry will be performed using Ima-
geScope version 10 (Aperio, Vista, CA, USA) [4, 14]. In
all cases, the mesentery will be laid out flat without
stretching, and the site of the tumour and HVTs will be
identifiable. The distance from the tumour and the clos-
est bowel wall to the HVT, the length of the large and
Fig. 3 Grouping of the retrieved lymph nodes
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small bowel, and the area of mesentery resected will be
accurately quantified.
Macroscopic quality of the mCME specimen
The quality of mCME will be graded based on the Med-
ical Research Council (MRC) CLASICC trial protocol
depending on the plane of excision, as described below
[4]. Mesocolic grading will be performed by the study
committee based on a review of the submitted photo-
graphs with blinding of patient outcome. Any discrepan-
cies between the two scores will be discussed before the
final grading.
 Mesocolic plane (grade A): an intact mesocolon
 Intramesocolic plane (grade B): significant mesocolic
disruptions away from the muscularis
 Muscularis propria plane (grade C): significant
disruptions extending down to the muscularis
Distribution of metastatic lymph nodes
The location of metastatic lymph nodes will be cate-
gorised into three levels based on the Japanese Classifi-
cation of Colorectal Carcinoma (Fig. 3) [15].
 Pericolic lymph nodes: lymph nodes along the
marginal arteries and vasa recta of the colon; those
on both proximal and distal sides of the primary
tumour, which are subcategorised in 5-cm intervals
from the edge of the primary tumour.
 Intermediate lymph nodes: lymph nodes along the
colic arteries
 Central lymph nodes: lymph nodes at the origin of
each colic artery
Adjuvant chemotherapy
Adjuvant chemotherapy will be administered based on
each patient’s pathologic report and the National Com-
prehensive Cancer Network guideline [16].
No patient with stage I disease will plan for adju-
vant chemotherapy. Patients with stage II–III disease
will receive adjuvant chemotherapy using either 5-FU/
leucovorin or 5-FU/oxaliplatin/leucovorin (FOLFOX)
on a 2-week cycle for 12 cycles, which will be selected
based on patient/physician discussions. Adjuvant
chemotherapy will be recommended for patients with
high-risk stage II tumours, as characterized by poorly
differentiated histology (exclusive of cancers that are
MSI-H), lymphovascular or perineural invasion, as
well as < 12 examined lymph nodes or positive mar-
gins. FOLFOX will be recommended for patients with
stage III disease, except for those in whom oxaliplatin
is contraindicated due to old age, poor performance
status, or pre-existing peripheral neuropathy.
Follow-up
Patients will be scheduled for follow-up every 3 months
after surgery until 3 years postoperatively. Complete
blood count, blood biochemical examination (aspartate
aminotransferase, alanine aminotransferase, creatinine,
blood urea nitrogen, blood glucose, and cholesterol), and
serum tumour marker (carcinoembryonic antigen) ana-
lyses will be performed every 3 months. Further, chest
radiography, abdominopelvic computed tomography,
and chest computed tomography will be performed
every 6 months, and colonoscopy will be performed
yearly. All results will be recorded and evaluated by a
specialist.
Fig. 4 (a) Anterior and (b) posterior photographs of a fresh laparoscopic modified complete mesocolic excision specimen taken with a metric
scale. The caecal tumour and ileocolic vascular tie are indicated by forceps. Note the smooth posterior surgical margin and intact
peritoneal window
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Discussion
High-quality surgery with the correct surgical plane im-
proves the treatment outcomes for patients with colorec-
tal cancer [4, 14]. Therefore, surgical quality evaluation
is essential in clinical studies introducing a new surgical
technique or evaluating existing procedures and is one
of the key factors for success. Well-designed studies
have applied strict qualification criteria for participating
surgeons who have completed a learning curve for a spe-
cific procedure and make great efforts to investigate the
quality of surgery as an objective indicator [4, 17]. How-
ever, it is difficult to objectively assess the quality of sur-
gery and there are no common indicators yet.
Several studies have shown the oncological safety and
feasibility of laparoscopic colon cancer surgery com-
pared with conventional open surgery [18, 19]. However,
prospective studies evaluating the safety and feasibility
of laparoscopic CME, Japanese D3 dissection, and
mCME in right-sided colon cancer surgery are rare. Fur-
thermore, there are few studies involving quality assess-
ments of right-sided colon cancer surgery using
objective measures, and there have not been any defini-
tive clinical studies evaluating surgical quality using in-
traoperative photographs in laparoscopic right-sided
colon cancer surgery.
The PIONEER study is a multi-institutional, prospect-
ive, single-arm study evaluating oncologic outcomes
after laparoscopic mCME for adenocarcinoma arising
from the right side of the colon (defined as from the cae-
cum up to the proximal half of the transverse colon). Re-
markably, the study will also evaluate the quality of
surgery with objective and rigorous indicators of laparo-
scopic mCME performed by certified surgeons, which
will ultimately demonstrate the significance of surgical
quality in treatment outcomes.
Notable previous randomised controlled trials com-
paring open and laparoscopic colorectal surgery con-
fined the criterion for participating surgeons to
performing at least 20 laparoscopic resections [17–
19]. However, in this study, only surgeons who per-
formed at least 50 cases of laparoscopic mCME were
qualified to participate; therefore, a more stringent
criterion was applied here as compared to other pre-
vious prospective studies. Moreover, this study adopts
a dual-valuation system based on photographs of the
surgical field taken during the operation and those of
the resected specimens, to maintain the surgical qual-
ity and to improve the objectivity of evaluation. For
surgeons participating in the PIONEER study, submit-
ting three photographs is mandatory. Photographs to
be submitted include a photograph of lymph node
dissection and photographs of the front and back
sides of the resected surgical specimen for surgical
quality control and assurance.
The completeness of mCME will be graded based on
the MRC CLASICC trial protocol, by reviewing the pho-
tographs of the resected surgical specimen primarily by
a pathologist at each centre and finally by central re-
viewers [4]. The mCME procedure follows the salient
concept of the original CME technique (oncologic resec-
tion with careful dissection of the mesocolon along the
embryologic planes resulting in the complete mobilisa-
tion of the mesocolon covered by an intact visceral fascia
layer containing all blood vessels, lymphatic vessels, and
lymph nodes that may contain disseminated cancer cells)
but with a more tailored approach [2, 10]. Therefore,
evaluating the smoothness of the fascia covering the
resected mesocolon is considered a powerful method for
assessing the completeness of mCME, which is a good
prognostic factor for colon cancer [4, 14]. However, the
weakness of this grading system is that even if the
peritoneal-lined mesentery and fascia covering the meso-
colon are intact, it does not assess the tumour involve-
ment of the radial margin, which is a risk factor for
recurrence [20]. The mCME has different features from
the original CME, one of which is securing an adequate
radial margin [10]. Consequently, this study is expected
to achieve a clearer evaluation of the quality of laparo-
scopic right-sided colon cancer surgery by overcoming
the weakness of the mesocolic grading system.
Precise quantitation of the resected surgical specimen,
by measuring the total area of the resected mesocolon
and the distance from the muscularis propria to the
nearest mesenteric and radial margin, is an indicator of
surgical and oncological quality, as well as the measuring
plane of surgery and lymph node retrieval [14]. However,
considering the surgical principle that central ligation of
main supplying vessels reduces the risk of residual meta-
static lymph nodes and enables accurate staging, it is
very challenging to assess the extent of lymph node dis-
section and CVL by using tissue morphometry and the
number of retrieved lymph nodes. To assess the central
radicality of laparoscopic mCME, the surgical field after
lymph node dissection and specimen removal will be
reviewed primarily by the attending surgeon at each
centre and finally by central reviewers based on the pho-
tographs obtained during the procedure.
To our knowledge, this study will be the first prospect-
ive trial to assess the oncologic safety of laparoscopic
mCME for right-sided colon cancer, supported by the
thorough surgical quality control system of the study
group. Patient-tailored surgical treatment for right-sided
colon cancer can be developed based on the present
study results, including the determination of the optimal
extent of dissection and the extent of the lymphadenec-
tomy. Additionally, it may aid in the development of a
global standardised surgical procedure for right-sided
colon cancer.
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